Navigation Links
Partner in Medical Technology

Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel

ALLEGAN, Mich., March 17 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO ; TASE) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company bel...

Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand

NEWARK, Del., Dec. 3 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, announced it has retained a strategic financial partner to help it expand operations to meet the global biopharma demand for Isogen's services. Isogen has previously anno...

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

november is Pancreatic Cancer Awareness Month Oak Brook, Ill., Nov. 24 /PRNewswire-USNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) and the Pancreatic Cancer Action Network are teaming up this November to raise awareness about pancreatic cancer, educating patient...

American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time

WASHINGTON, BATTLE CREEK, Mich., and EVANSTON, Ill., Oct. 20 /PRNewswire/ -- The American College of Cardiology (ACC) and the Center of Excellence for Simulation Research (CESR) of Western Michigan University announced the launch of an educational and research partnership, using in situ simula...

Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer

BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough trea...

MTV and SpinVox Partner to Launch First Ever Integrated Voice Powered Cause-Related Social Networking Campaign 'Stand By What You Say'

CAMPAIGN VOICED BY SUPERSTAR KELLY ROWLAND 'CAUSES' PROMOTES CAMPAIGN TO ITS 12 MILLION MEMBERS LONDON and NEW YORK, June 10 /PRNewswire/ -- MTV's Staying Alive Foundation, SpinVox and Causes on Facebook today announced the launch of their joint campaign, 'Stand By What...

eHealth Initiative's Drug Safety Collaboration to Partner With FDA on Sentinel Initiative

eHI's multi-stakeholder "Connecting Communities for Drug Safety Collaboration" conducting drug safety pilots to test and evaluate use of electronic health information to support post-market monitoring efforts WASHINGTON, May 22 /PRNewswire-USNewswire/ -- The non-profit eHealth Initiative (eH...

Wayne State University and Oakwood Partner in New Device to Combat Congestive Heart Failure

DEARBORN, Mich., April 7, 2008 /PRNewswire-USNewswire/ -- Wayne State University School of Medicine and Oakwood Healthcare System surgeons successfully implanted a new device designed to combat congestive heart failure in a 49-year-old patient. The device could become a leading tool in the ars...

Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease

EMERYVILLE and NOVATO, Calif., March 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII ) and the Buck Institute for Age Research (Buck) announced today they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's ...

CMC, Moffitt Partner to Study Cancer

CHARLOTTE, N.C., Feb. 26 /PRNewswire-USNewswire/ -- The Blumenthal Cancer Center at Carolinas Medical Center (CMC) in Charlotte is partnering with the Moffitt Cancer Center in a study that could lead to individualized treatments for specific types of cancer. CMC is the first hospital system ou...

Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that its corporate partner, Pfizer (NYSE: PFE ), has begun a Phase 1 clinical trial of an inhaled formulation of Rigel's small molecule syk kinase inhibitor, R343, for th...

JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers

- $3 Million Grant Over Three Years from Lilly Foundation Could 'Fill a Major Gap' in Diabetes Science - NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- The Juvenile Diabetes Research Foundation and Eli Lilly and Company announced today that they are joining together to create a...

BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health

NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has submitted a Biologics License Application (BLA) for Naglazyme(R) (galsulfase) to the Ja...

AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx B...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner Cook Medical has completed target patient enrollment and released six-month follow-up data from a Phase II clinical trial known as Appraisal. The trial, currently being held in Germany...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

... "Through this collaboration with JDRF, we are looking to create a unique program of translational research that fully exploits the strengths of each partner to produce a continuous source of novel insights, drug targets, and drug candidates," said Peter Schultz, PhD, Lead GNF Investigator and Institute Dir...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...o obligation to, and do not currently intend to, update these forward-looking statements. Investor Contact: Hayden IR Jeff Stanlis, partner and VP of Communications (602)476-1821 jeff@haydenir.com ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... or delay or failure in obtaining regulatory approval in one or more important markets; (iii) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be require...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...er highly publicized assay on the market detects only seven. KRAS mutation-detection testing is just one example of how ARUP Laboratories can partner with laboratories and hospitals to improve patient care and decrease overall health care costs by helping reduce over-, under-, and misuse of laborato...

Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.

... will determine whether injecting the cells into the urethra would restore the contractility of the muscles and sphincters. "We are honored to partner with Cryopraxis, a global leader in regenerative medicine and stem cell R&D, to explore the utilization and potential commercialization of Cryo-Ce...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

...sitive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co., Ltd. of Osaka, Japan and conducted during the 2008-2009 influenza season. Shionogi and Green Cross Corporation, the license holde...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... Graeme McRae, Chairman, President & CEO of Bioniche, added, "Endo Pharmaceuticals represents the optimal development and commercialization partner for Bioniche, given its understanding of the bladder cancer market and breadth of pharmaceutical industry experience. We look forward to advancing the...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

...also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of 'companion diagnostic' tests. Strengthened by its first-rate scientif...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

... be completed TASKi3 clinical trial, a total of over 670 patients, will guide the design of the Phase 3 trials that we plan to launch with a corporate partner in the first half of next year, " he added. Efficacy Results Treatment N of Pts ACR 20 ACR 50 ACR 70 DAS28<2.6 ...

St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures

...ens the door to a new level of cardiac tissue reconstruction," said Gerdisch, director of cardiothoracic surgery at the St. Francis Heart Center and a partner at Cardiac Surgery Associates. In August 2007, Gerdisch, who specializes in complex heart valve surgery, became the first in the world to apply t...

Relievant Medsystems Announces Completion of $20 Million Financing

...g investors Canaan Partners and ONSET Ventures and new investor Emergent Medical Partners participating. The company also announced that Morgenthaler partner Hank Plain has joined its Board of Directors. "Capital raised will fund clinical research and the launch of our Intracept(TM) System to treat low...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

...rinary tract infections, which are usually caused by gram-negative pathogens". Eckard Weber, president and chief executive officer of Calixa and partner at the venture capital firm Domain Associates, LLC said, "With the continually increasing incidence of serious and life-threatening infections caused ...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

...d about the productivity and the science being generated by the scientists in our labs here in Hong Kong, and believe that HKUST has been an essential partner in generating this mutual success." According to Jeff Watkins, CEO of aTyr Pharma, "In just over a year from incorporation in Hong Kong, Pangu Bi...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

...es throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal. It is the partner of choice for many companies, having a strong presence in the Iberian peninsula as well as in over 10 countries in Latin America and in around 20 Fren...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

...reatment. A number of secondary endpoints will also be evaluated. NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. Novartis intends to launch NVA237 as a once-daily monotherapy for COPD and also in combination with Novartis' investigational once-daily, lon...

West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial

...y we monitor cardiac patients on a continuous and remote basis," added Topol. "Corventis believes in evidence-based medicine, and is delighted to partner with the West Wireless Health Institute, and leading clinical centers on this important clinical research initiative," said Ed Manicka, Ph.D., preside...

Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)

...gy Officer, will lead the development effort as Cytel Principal Investigator. Dr. Patel commented, "We are honored that CDRH chose Cytel as their partner for developing validated, documented, and commercially available Bayesian software. The CRADA is completely aligned with our vision of implementing in...

CoAxia, Inc. Announces $21.5M Series D Financing

... believe that we are now well positioned for trial completion, PMA submission and initiation of sales and marketing." Antoine Papiernik, Managing partner at Sofinnova Partners commented: "Sofinnova is pleased to have led the Series D round for CoAxia. We have long been interested in treatment opportunit...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

..., including the THR beta agonist candidate and the other compounds licensed from Roche; -- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291; -- our ability to form and maintai...

ThermoGenesis Announces National Institute of Health Grant

...stem cells in a closed system. The AXP device is used for the processing of umbilical cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product, except Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. ...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

...lpha-blockers, anti-hypertensives and potent inhibitors of CYP3A4) and with substantial amounts of alcohol. CIALIS does not protect a man or his partner from sexually transmitted diseases, including HIV. Men should not drink alcohol in excess with CIALIS. The most common side effects with CIALIS were ...

New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform

... "We gave Americans a list of proposals being considered to reform health care, and investing in prevention trumped them all," said Bill McInturff, partner and Co-Founder of Public Opinion Strategies. "It's clear that Americans see the value of prevention for reducing disease, improving quality of life, a...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's abil...

CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement

...ented virtually at the annual CICT conference BOSTON, June 2 /PRNewswire/ -- The EndoVascular Forum, Inc. (EVF), an IC Sciences Company, and its partner Complex Interventional Cardiovascular Therapy (CICT) announced a collaboration using EVF's CardioVascularCS.Org operating division to extend the influ...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

... be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's abil...
Other Tags
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
(Date:4/23/2014)... first cause of dementia and affects some 400,000 people ... been found. One of the reasons for this is ... cause alterations in nerve transmissions and the loss of ... from the Institute of Neuroscience at the Universitat Autnoma ... memory consolidation and were able to develop a gene ...
(Date:4/23/2014)... many social mammals, ravens form different types of social ... and they also form strict dominance relations. From a ... a key ability in daily social life ("knowing who ... group members have with each other sets the stage ... results of this study have been published in the ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2Ravens understand the relations among others 2
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington will ... of Concept grants to accelerate maturation of promising ... Life Sciences Discovery Fund (LSDF) announced today. Also ... to the Washington Biotechnology & Biomedical Association (WBBA) ... the next generation of entrepreneurs and help early-stage ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
Other Contents